Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Summary
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
Official title: Fecal Microbiota Transplantation （FMT） Combined With QL1706 Plus Bevacizumab as First-line Treatment for Advanced HCC
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-10-10
Completion Date
2031-10
Last Updated
2026-10-08
Healthy Volunteers
No
Conditions
Interventions
FMT combined with QL1706 plus Bevacizumab
Oral Fecal Microbiota Transplantation （FMT） capsules: Full-dose FMT (80-100g) will be administered on Days 0,28, and 49. Iparomlimab and Tuvonralimab （QL1706）: QL1706 will be administered intravenously at a dose of 7.5 mg/kg, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days. Bevacizumab: Bevacizumab will be administered intravenously at a dose of 15 mg/kg body weight, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days.
Locations (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China